{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:46:10Z","timestamp":1790721970853,"version":"4.1.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1208\/s12248-017-0056-x","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T19:52:35Z","timestamp":1487706755000},"page":"669-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies"],"prefix":"10.1208","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-8562","authenticated-orcid":false,"given":"Rui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Waye","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"issue":"9844","key":"56_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848\u201357.","journal-title":"Lancet"},{"key":"56_CR2","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.","edition":"4"},{"issue":"6","key":"56_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1\u20132 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981\u20137.","journal-title":"Blood"},{"key":"56_CR4","first-page":"w13511","volume":"142","author":"U Mey","year":"2012","unstructured":"Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, et al. Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly. 2012;142:w13511.","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"56_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34(11):1256\u201369.","journal-title":"J Clin Oncol"},{"issue":"26","key":"56_CR6","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","volume":"23","author":"B Coiffier","year":"2005","unstructured":"Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23(26):6387\u201393.","journal-title":"J Clin Oncol"},{"issue":"29","key":"56_CR7","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","volume":"25","author":"PA Tang","year":"2007","unstructured":"Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol. 2007;25(29):4562\u20138.","journal-title":"J Clin Oncol"},{"issue":"33","key":"56_CR8","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007;25(33):5218\u201324.","journal-title":"J Clin Oncol"},{"key":"56_CR9","volume-title":"Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model","author":"NIH Definitions Working Group","year":"2000","unstructured":"NIH Definitions Working Group. In: Downing G, editor. Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model. Amsterdam: Elsevier; 2000."},{"issue":"12","key":"56_CR10","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, L\u00fcck HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987\u201392.","journal-title":"J Clin Oncol"},{"issue":"4","key":"56_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S0266462308080495","volume":"24","author":"RA Miksad","year":"2008","unstructured":"Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24(4):371\u201383.","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"56_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JTO.0b013e3181989bd2","volume":"4","author":"K Hotta","year":"2009","unstructured":"Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009;4(3):311\u20137.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"56_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdp523","volume":"21","author":"ED Saad","year":"2010","unstructured":"Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21(1):7\u201312.","journal-title":"Ann Oncol"},{"issue":"9","key":"56_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","volume":"7","author":"KR Johnson","year":"2006","unstructured":"Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7(9):741\u20136.","journal-title":"Lancet Oncol"},{"issue":"23","key":"56_CR15","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/jnci\/djp369","volume":"101","author":"KR Broglio","year":"2009","unstructured":"Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101(23):1642\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"56_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","volume":"16","author":"K Han","year":"2014","unstructured":"Han K, Ren M, Wick W, Abrey L, Das A, Jin J, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014;16(5):696\u2013706.","journal-title":"Neuro Oncol"},{"issue":"6","key":"56_CR17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","volume":"22","author":"L Lee","year":"2011","unstructured":"Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol. 2011;22(6):1392\u2013403.","journal-title":"Ann Oncol"},{"key":"56_CR18","unstructured":"PRISMA: Transparent reporting of systematic reviews and meta-analyses. Available from: http:\/\/www.prisma-statement.org ."},{"issue":"3","key":"56_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1214\/ss\/1032280214","volume":"11","author":"T DiCiccio","year":"1996","unstructured":"DiCiccio T, Efron B. Bootstrap confidence intervals. Stat Sci. 1996;11(3):189\u2013212.","journal-title":"Stat Sci"},{"issue":"10","key":"56_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cem.663","volume":"15","author":"F Rio del","year":"2001","unstructured":"del Rio F, Riu J, Rius F. Prediction intervals in linear regression taking into account errors on both axes. J Chemom. 2001;15(10):773\u201388.","journal-title":"J Chemom"},{"issue":"3","key":"56_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 2008;113(3):508\u201314.","journal-title":"Cancer"},{"issue":"4","key":"56_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol. 2011;12(4):361\u20138.","journal-title":"Lancet Oncol"},{"issue":"4","key":"56_CR23","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2012.075184","volume":"98","author":"JA Barnes","year":"2013","unstructured":"Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98(4):615\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"56_CR24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdl316","volume":"18","author":"A Belch","year":"2007","unstructured":"Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol. 2007;18(1):116\u201321.","journal-title":"Ann Oncol"},{"issue":"8","key":"56_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/oxfordjournals.annonc.a010757","volume":"7","author":"DC Betticher","year":"1996","unstructured":"Betticher DC, Zucca E, von Rohr A, Egger T, Radford JA, Ambrosetti A, et al. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin\u2019s lymphoma. Ann Oncol. 1996;7(8):793\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"56_CR26","first-page":"496","volume":"91","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91(4):496\u2013502.","journal-title":"Haematologica"},{"issue":"16","key":"56_CR27","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","volume":"26","author":"G Cartron","year":"2008","unstructured":"Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouill\u00e9 V, Quittet P, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol. 2008;26(16):2725\u201331.","journal-title":"J Clin Oncol"},{"issue":"12","key":"56_CR28","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1002\/cncr.26510","volume":"118","author":"BD Cheson","year":"2012","unstructured":"Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer. 2012;118(12):3128\u201334.","journal-title":"Cancer"},{"issue":"8","key":"56_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol. 2011;12(8):773\u201384.","journal-title":"Lancet Oncol"},{"issue":"5","key":"56_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2141.2011.08786.x","volume":"154","author":"G Corazzelli","year":"2011","unstructured":"Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high \u2018life threat\u2019 impact cardiopathy. Br J Haematol. 2011;154(5):579\u201389.","journal-title":"Br J Haematol"},{"issue":"3","key":"56_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.bmt.1705414","volume":"38","author":"D Coso","year":"2006","unstructured":"Coso D, Sebban C, Boulat O, Biron P, Rey J, Aurran T, et al. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplant. 2006;38(3):217\u201322.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"56_CR32","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1023\/A:1008381105849","volume":"11","author":"CR Crawley","year":"2000","unstructured":"Crawley CR, Foran JM, Gupta RK, Rohatiner AZ, Summers K, Matthews J, et al. A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol. 2000;11(7):861\u20135.","journal-title":"Ann Oncol"},{"issue":"8","key":"56_CR33","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004;101(8):1835\u201342.","journal-title":"Cancer"},{"issue":"16","key":"56_CR34","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1182\/blood-2011-09-378323","volume":"119","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16):3698\u2013704.","journal-title":"Blood"},{"issue":"4","key":"56_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1365-2141.2012.09086.x","volume":"157","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438\u201345.","journal-title":"Br J Haematol"},{"issue":"9","key":"56_CR36","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","volume":"23","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2012;23(9):2356\u201362.","journal-title":"Ann Oncol"},{"issue":"17","key":"56_CR37","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-L\u00f3pez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18(17):3135\u201343.","journal-title":"J Clin Oncol"},{"issue":"30","key":"56_CR38","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","volume":"27","author":"S Vos de","year":"2009","unstructured":"de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023\u201330.","journal-title":"J Clin Oncol"},{"issue":"6","key":"56_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","volume":"14","author":"R Delarue","year":"2013","unstructured":"Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14(6):525\u201333.","journal-title":"Lancet Oncol"},{"issue":"3","key":"56_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood-2009-08-233155","volume":"115","author":"N Bella Di","year":"2010","unstructured":"Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115(3):475\u201380.","journal-title":"Blood"},{"issue":"5","key":"56_CR41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2009.12.530","volume":"16","author":"MS Dilhuydy","year":"2010","unstructured":"Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, et al. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final results of a phase II GOELAMS Study. Biol Blood Marrow Transplant. 2010;16(5):672\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"56_CR42","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3816\/CLM.2003.n.026","volume":"4","author":"R Drapkin","year":"2003","unstructured":"Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, et al. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin\u2019s lymphoma: an effective and minimally toxic regimen. Clin Lymphoma. 2003;4(3):169\u201375.","journal-title":"Clin Lymphoma"},{"issue":"1","key":"56_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1658-3876(10)50051-7","volume":"3","author":"NA Bary El","year":"2010","unstructured":"El Bary NA, Hashem T, Metwally H, Ghany AA, El Mageed HA. A phase II study of high-dose celecoxib and metronomic \u2018low-dose\u2019 cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma. Hematol Oncol Stem Cell Ther. 2010;3(1):13\u20138.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"8","key":"56_CR44","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","volume":"18","author":"T Gnaoui El","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363\u20138.","journal-title":"Ann Oncol"},{"issue":"9","key":"56_CR45","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002770000163","volume":"79","author":"M Feuring-Buske","year":"2000","unstructured":"Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol. 2000;79(9):493\u2013500.","journal-title":"Ann Hematol"},{"issue":"2","key":"56_CR46","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18(2):317\u201324.","journal-title":"J Clin Oncol"},{"issue":"10","key":"56_CR47","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, H\u00e4nel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064\u201371.","journal-title":"Blood"},{"issue":"25","key":"56_CR48","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011;29(25):3389\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"56_CR49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520\u20135.","journal-title":"Ann Oncol"},{"issue":"4","key":"56_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(4):667\u201375.","journal-title":"J Clin Oncol"},{"issue":"8","key":"56_CR51","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","volume":"95","author":"R Gressin","year":"2010","unstructured":"Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, et al. Evaluation of the (R)VAD\u2009+\u2009C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica. 2010;95(8):1350\u20137.","journal-title":"Haematologica"},{"issue":"19","key":"56_CR52","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"56_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","volume":"10","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, et al. Brief-duration rituximab\/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma Leuk. 2010;10(1):44\u201350.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"56_CR54","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1200\/JCO.2005.05.004","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin\u2019s lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(7):1500\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"56_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00432-009-0637-x","volume":"136","author":"T Hara","year":"2010","unstructured":"Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, et al. Phase II study of rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma. J Cancer Res Clin Oncol. 2010;136(1):65\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"56_CR56","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986\u201392.","journal-title":"J Clin Oncol"},{"issue":"23","key":"56_CR57","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(23):3822\u20139.","journal-title":"J Clin Oncol"},{"issue":"12","key":"56_CR58","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725\u201332.","journal-title":"Blood"},{"issue":"6","key":"56_CR59","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/annonc\/mdr450","volume":"23","author":"R Houot","year":"2012","unstructured":"Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD\u2009+\u2009C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012;23(6):1555\u201361.","journal-title":"Ann Oncol"},{"issue":"5","key":"56_CR60","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20(5):1288\u201394.","journal-title":"J Clin Oncol"},{"issue":"11","key":"56_CR61","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3109\/10428194.2011.589549","volume":"52","author":"R Karmali","year":"2011","unstructured":"Karmali R, Larson ML, Wooldridge JE, Gregory SA, O\u2019Brien T, Shammo JM, et al. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2011;52(11):2097\u2013104.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"56_CR62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3109\/10428194.2011.555024","volume":"52","author":"S Kasahara","year":"2011","unstructured":"Kasahara S, Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, et al. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011;52(4):629\u201334.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"56_CR63","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","volume":"21","author":"CT Kouroukis","year":"2003","unstructured":"Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21(9):1740\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"56_CR64","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3109\/10428194.2010.546015","volume":"52","author":"CT Kouroukis","year":"2011","unstructured":"Kouroukis CT, Fernandez LA, Crump M, Gascoyne RD, Chua NS, Buckstein R, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma. 2011;52(3):394\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"56_CR65","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/annonc\/mdm114","volume":"18","author":"JP Leonard","year":"2007","unstructured":"Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, et al. A phase I\/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007;18(7):1216\u201323.","journal-title":"Ann Oncol"},{"issue":"2","key":"56_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","volume":"80","author":"A L\u00f3pez","year":"2008","unstructured":"L\u00f3pez A, Guti\u00e9rrez A, Palacios A, Blancas I, Navarrete M, Morey M, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008;80(2):127\u201332.","journal-title":"Eur J Haematol"},{"issue":"9","key":"56_CR67","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/cncr.24222","volume":"115","author":"S Luminari","year":"2009","unstructured":"Luminari S, Marcheselli L, Sacchi S, Pozzi S, Bari A, Ilariucci F, et al. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. Cancer. 2009;115(9):1906\u201313.","journal-title":"Cancer"},{"issue":"7","key":"56_CR68","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","volume":"21","author":"S Luminari","year":"2010","unstructured":"Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010;21(7):1492\u20139.","journal-title":"Ann Oncol"},{"issue":"4","key":"56_CR69","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417\u201323.","journal-title":"Blood"},{"issue":"2","key":"56_CR70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/10428190601078100","volume":"48","author":"F Merli","year":"2007","unstructured":"Merli F, Bertini M, Luminari S, Mozzana R, Botto B, Liberati AM, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48(2):367\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"56_CR71","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/07357900600814490","volume":"24","author":"UJ Mey","year":"2006","unstructured":"Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. Cancer Invest. 2006;24(6):593\u2013600.","journal-title":"Cancer Invest"},{"issue":"15","key":"56_CR72","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","volume":"118","author":"IN Micallef","year":"2011","unstructured":"Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053\u201361.","journal-title":"Blood"},{"issue":"5","key":"56_CR73","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/10428190802007700","volume":"49","author":"PL Mitchell","year":"2008","unstructured":"Mitchell PL, Marlton P, Grigg A, Seymour JF, Hertzberg M, Enno A, et al. A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2008;49(5):924\u201331.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"56_CR74","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3324\/haematol.11671","volume":"93","author":"S Montoto","year":"2008","unstructured":"Montoto S, Moreno C, Domingo-Dom\u00e9nech E, Estany C, Oriol A, Alt\u00e9s A, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008;93(2):207\u201314.","journal-title":"Haematologica"},{"issue":"18","key":"56_CR75","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1002\/cncr.25280","volume":"116","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, et al. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent\/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) and Groupe Ouest Est des Leuc\u00e9mies et Autres Maladies du Sang (GOELAMS). Cancer. 2010;116(18):4299\u2013308.","journal-title":"Cancer"},{"issue":"2","key":"56_CR76","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/annonc\/mdm463","volume":"19","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, Pfreundschuh M, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol. 2008;19(2):247\u201353.","journal-title":"Ann Oncol"},{"issue":"11","key":"56_CR77","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","volume":"98","author":"N Mounier","year":"2013","unstructured":"Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726\u201331.","journal-title":"Haematologica"},{"issue":"2","key":"56_CR78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hon.940","volume":"28","author":"N Niitsu","year":"2010","unstructured":"Niitsu N, Kohri M, Hagiwara Y, Tanae K, Takahashi N, Bessho M, et al. Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2010;28(2):68\u201374.","journal-title":"Hematol Oncol"},{"issue":"9","key":"56_CR79","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1349-7006.2006.00249.x","volume":"97","author":"N Niitsu","year":"2006","unstructured":"Niitsu N, Kohuri M, Higashihara M, Bessho M. Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Sci. 2006;97(9):933\u20137.","journal-title":"Cancer Sci"},{"issue":"2","key":"56_CR80","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-08-2647","volume":"16","author":"OA O\u2019Connor","year":"2010","unstructured":"O\u2019Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16(2):719\u201326.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"56_CR81","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","volume":"97","author":"M Ogura","year":"2006","unstructured":"Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci. 2006;97(4):305\u201312.","journal-title":"Cancer Sci"},{"issue":"3","key":"56_CR82","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1532\/IJH97.04077","volume":"80","author":"M Ogura","year":"2004","unstructured":"Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin\u2019s lymphomas: results of a Japanese phase II study. Int J Hematol. 2004;80(3):267\u201377.","journal-title":"Int J Hematol"},{"issue":"9","key":"56_CR83","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101(9):2059\u201364.","journal-title":"Cancer Sci"},{"issue":"17","key":"56_CR84","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"56_CR85","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1200\/JCO.1993.11.11.2250","volume":"11","author":"SE O\u2019Reilly","year":"1993","unstructured":"O\u2019Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P\/DOCE chemotherapy. J Clin Oncol. 1993;11(11):2250\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"56_CR86","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/mpo.2950220403","volume":"22","author":"H Ozer","year":"1994","unstructured":"Ozer H, Anderson JR, Peterson BA, Budman DR, Cooper MR, Kennedy BJ, et al. Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin\u2019s lymphoma. Med Pediatr Oncol. 1994;22(4):228\u201335.","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"56_CR87","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460\u20138.","journal-title":"Lancet Oncol"},{"issue":"4","key":"56_CR88","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/1078-0432.CCR-0977-03","volume":"10","author":"M Pless","year":"2004","unstructured":"Pless M, Belhadj K, Menssen HD, Kern W, Coiffier B, Wolf J, et al. Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma: results from a phase II multicenter study. Clin Cancer Res. 2004;10(4):1299\u2013305.","journal-title":"Clin Cancer Res"},{"issue":"9806","key":"56_CR89","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","volume":"378","author":"C R\u00e9cher","year":"2011","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, Molina TJ, Ferm\u00e9 C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858\u201367.","journal-title":"Lancet"},{"issue":"7","key":"56_CR90","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, et al. A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica. 2012;97(7):1085\u201391.","journal-title":"Haematologica"},{"issue":"27","key":"56_CR91","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(27):4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"56_CR92","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.10137","volume":"70","author":"N Rohatgi","year":"2002","unstructured":"Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Am J Hematol. 2002;70(3):181\u20135.","journal-title":"Am J Hematol"},{"issue":"28","key":"56_CR93","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013\u201323.","journal-title":"J Clin Oncol"},{"issue":"11","key":"56_CR94","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1002\/cncr.25055","volume":"116","author":"J Ruan","year":"2010","unstructured":"Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116(11):2655\u201364.","journal-title":"Cancer"},{"issue":"6","key":"56_CR95","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","volume":"29","author":"J Ruan","year":"2011","unstructured":"Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(6):690\u20137.","journal-title":"J Clin Oncol"},{"issue":"15","key":"56_CR96","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23(15):3383\u20139.","journal-title":"J Clin Oncol"},{"issue":"13","key":"56_CR97","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0959-8049(02)00143-0","volume":"38","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Karakas T, J\u00e4ger E, Mezger J, von Gr\u00fcnhagen U, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin\u2019s lymphoma. Eur J Cancer. 2002;38(13):1739\u201346.","journal-title":"Eur J Cancer"},{"issue":"9873","key":"56_CR98","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"1","key":"56_CR99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cncr.22740","volume":"110","author":"S Sacchi","year":"2007","unstructured":"Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007;110(1):121\u20138.","journal-title":"Cancer"},{"issue":"25","key":"56_CR100","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1200\/JCO.2010.33.6594","volume":"29","author":"LH Sehn","year":"2011","unstructured":"Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2011;29(25):3396\u2013401.","journal-title":"J Clin Oncol"},{"issue":"10","key":"56_CR101","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1080\/10428190903093807","volume":"50","author":"SM Smith","year":"2009","unstructured":"Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, et al. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009;50(10):1606\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"31","key":"56_CR102","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin\u2019s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"56_CR103","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","volume":"14","author":"P Solal-C\u00e9ligny","year":"1996","unstructured":"Solal-C\u00e9ligny P, Brice P, Brousse N, Caspard H, Bastion Y, Ha\u00efoun C, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1996;14(2):514\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"56_CR104","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1056\/NEJM199311253292203","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. N Engl J Med. 1993;329(22):1608\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"56_CR105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10428190902856808","volume":"50","author":"AT Stopeck","year":"2009","unstructured":"Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma. 2009;50(5):728\u201335.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"56_CR106","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","volume":"120","author":"AT Stopeck","year":"2012","unstructured":"Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012;120(6):1210\u20137.","journal-title":"Blood"},{"issue":"24","key":"56_CR107","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2006;24(24):3880\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"56_CR108","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12185-012-1119-5","volume":"96","author":"S Takemura","year":"2012","unstructured":"Takemura S, Tomita N, Koharazawa H, Fujimaki K, Harano H, Hyo R, et al. Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma. Int J Hematol. 2012;96(2):241\u20136.","journal-title":"Int J Hematol"},{"key":"56_CR109","doi-asserted-by":"crossref","unstructured":"MacDonald D, van der Jagt R, Burke JM, Kahl BS, Wood P, Hawkins TE, et al. Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): the BRIGHT study. J Clin Oncol. 2013;31(suppl; abstr 8565).","DOI":"10.1200\/jco.2013.31.15_suppl.8565"},{"issue":"10","key":"56_CR110","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/j.1349-7006.2009.01247.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, et al. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci. 2009;100(10):1951\u20136.","journal-title":"Cancer Sci"},{"issue":"3","key":"56_CR111","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/hon.815","volume":"25","author":"H Tsurumi","year":"2007","unstructured":"Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25(3):107\u201314.","journal-title":"Hematol Oncol"},{"issue":"2","key":"56_CR112","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/10428194.2011.606383","volume":"53","author":"H Tsurumi","year":"2012","unstructured":"Tsurumi H, Hara T, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, et al. A phase II study of rituximab combined with pirarubicin-cyclophosphamide, vincristine and prednisolone regimen as first-line therapy for patients with indolent B-cell lymphoma. Leuk Lymphoma. 2012;53(2):247\u201353.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"56_CR113","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93(3):403\u20139.","journal-title":"Ann Hematol"},{"issue":"10","key":"56_CR114","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/cncr.23880","volume":"113","author":"M Wang","year":"2008","unstructured":"Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, et al. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008;113(10):2734\u201341.","journal-title":"Cancer"},{"issue":"7","key":"56_CR115","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012;13(7):716\u201323.","journal-title":"Lancet Oncol"},{"issue":"30","key":"56_CR116","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1200\/JCO.2011.34.8508","volume":"29","author":"T Watanabe","year":"2011","unstructured":"Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, et al. Phase II\/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin\u2019s lymphoma: JCOG 0203 trial. J Clin Oncol. 2011;29(30):3990\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"56_CR117","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"R Weide","year":"2007","unstructured":"Weide R, Hess G, K\u00f6ppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48(7):1299\u2013306.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"56_CR118","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3816\/CLM.2002.n.004","volume":"2","author":"DD Wilder","year":"2002","unstructured":"Wilder DD, Ogden JL, Jain VK. Efficacy of fludarabine\/mitoxantrone\/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin\u2019s lymphoma. Clin Lymphoma. 2002;2(4):229\u201337.","journal-title":"Clin Lymphoma"},{"issue":"16","key":"56_CR119","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","volume":"26","author":"WH Wilson","year":"2008","unstructured":"Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"56_CR120","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/leu.2010.226","volume":"25","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341\u20137.","journal-title":"Leukemia"},{"issue":"7","key":"56_CR121","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2011;22(7):1622\u20137.","journal-title":"Ann Oncol"},{"issue":"6","key":"56_CR122","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005;23(6):1103\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"56_CR123","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bjc.6602031","volume":"91","author":"L Yung","year":"2004","unstructured":"Yung L, Cunningham D, Hancock B, Smith P, Maclennan K, Linch D, et al. Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI). Br J Cancer. 2004;91(4):695\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"56_CR124","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3324\/haematol.2011.051813","volume":"97","author":"F Zaja","year":"2012","unstructured":"Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97(3):416\u201322.","journal-title":"Haematologica"},{"issue":"10","key":"56_CR125","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1080\/10428190600799946","volume":"47","author":"F Zaja","year":"2006","unstructured":"Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(10):2174\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"56_CR126","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1023\/A:1008228709612","volume":"8","author":"PL Zinzani","year":"1997","unstructured":"Zinzani PL, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin\u2019s lymphoma. Ann Oncol. 1997;8(4):379\u201383.","journal-title":"Ann Oncol"},{"issue":"6769","key":"56_CR127","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503\u201311.","journal-title":"Nature"},{"issue":"9","key":"56_CR128","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","volume":"13","author":"K Spaepen","year":"2002","unstructured":"Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Ann Oncol. 2002;13(9):1356\u201363.","journal-title":"Ann Oncol"},{"issue":"4","key":"56_CR129","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","volume":"106","author":"C Haioun","year":"2005","unstructured":"Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376\u201381.","journal-title":"Blood"},{"issue":"9","key":"56_CR130","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1093\/annonc\/mdi272","volume":"16","author":"NG Mikhaeel","year":"2005","unstructured":"Mikhaeel NG, Hutchings M, Fields PA, O\u2019Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16(9):1514\u201323.","journal-title":"Ann Oncol"},{"issue":"3","key":"56_CR131","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","volume":"41","author":"C Tychyj-Pinel","year":"2014","unstructured":"Tychyj-Pinel C, Ricard F, Fulham M, Fournier M, Meignan M, Lamy T, et al. PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"56_CR132","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"issue":"27","key":"56_CR133","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"56_CR134","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-62703-269-8_10","volume":"971","author":"C Pott","year":"2013","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR. Methods Mol Biol. 2013;971:175\u2013200.","journal-title":"Methods Mol Biol"},{"issue":"9","key":"56_CR135","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"56_CR136","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/psp4.12041","volume":"5","author":"M Boucher","year":"2016","unstructured":"Boucher M, Bennetts M. The many flavors of model-based meta-analysis: part I\u2014introduction and landmark data. CPT Pharmacometrics Syst Pharmacol. 2016;5(2):54\u201364.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"56_CR137","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007;9(1):29\u201338.","journal-title":"Neuro Oncol"},{"issue":"24","key":"56_CR138","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO;2-V","volume":"15","author":"M Buyse","year":"1996","unstructured":"Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med. 1996;15(24):2797\u2013812.","journal-title":"Stat Med"},{"issue":"1","key":"56_CR139","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics. 2000;1(1):49\u201367.","journal-title":"Biostatistics"},{"issue":"1","key":"56_CR140","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/1467-985X.00153","volume":"163","author":"CB Begg","year":"2000","unstructured":"Begg CB, Leung DHY. On the use of surrogate endpoints in randomized trials. J R Stat Soc Ser A-G. 2000;163(1):15\u201328.","journal-title":"J R Stat Soc Ser A-G"},{"key":"56_CR141","doi-asserted-by":"publisher","unstructured":"Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Medical Research Methodology. 2003;3(16).","DOI":"10.1186\/1471-2288-3-16"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-017-0056-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-017-0056-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T16:11:39Z","timestamp":1719072699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-017-0056-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1208\/s12248-017-0056-x","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]}}}